Navigation Links
Carrington Subsidiary DelSite to Present at Investor Conference
Date:11/1/2007

IRVING, Texas, Nov. 1 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7th, at 2:00 pm Eastern Time at the New York Palace Hotel.

The presentation will cover three key platform technologies in the areas of drug delivery and vaccine adjuvants, and will also provide information on the Company and the development status of its lead product candidate.

DelSite specializes in the development of novel liquid and powder formulations for protein/peptide therapeutics and vaccines using its proprietary platform technologies. So far this year, DelSite has signed six technology rights evaluation agreements with commercial partners and institutions that are interested in its delivery technology.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. It also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital-intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington
'/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... SNM,s 57th Annual Meeting WHAT: Registration to the ... openand freefor members of the media WHEN: June ... Lake City, Utah MORE INFO: Registration is free ... letter of assignment. The online meeting planner is available ...
... more, not less, use, study finds , FRIDAY, March ... can backfire, suggests a U.S. study. , Researchers interviewed ... ads that used guilt or shame to warn against ... instinctive coping mechanism that enables people who see them ...
... ... ... ... ...
... TEMPE, Ariz. Leading futurists and technologists have worked ... "Grand Challenges for Engineering in the 21st Century," focusing ... improve the quality of life in a growing and ... to action toward achieving these goals, the Ira A. ...
... can lead to unneeded treatments with unwanted side ... -- New American Cancer Society guidelines on prostate ... faced with a cascade of decisions, with a ... shoulders. , The guidelines, issued Wednesday, de-emphasize routine ...
... ... --HealthCare Partners of Nevada, a Las Vegas-based healthcare organization, announced the acquisition of Rainbow Medical ... Nevada. Rainbow Medical Center is now part of the Fremont Medical Centers Division of ... ...
Cached Medicine News:Health News:Anti-Drinking Ads That Engender Guilt May Not Work 2Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 2Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 3Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 4Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 5Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 6Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 7Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 8Health News:Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates 9Health News:Summit seeks to spark call to action on facing world's biggest challenges 2Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 2Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 3Health News:New Prostate Cancer Guidelines Aim to Empower the Patient 4Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 /PRNewswire/ ... they have entered into a license and collaboration ... target cancers. PhosImmune possesses technology for ... surfaces of tumor cells in association with HLA ... proteins that play a role in malignancy, are ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014  Indianapolis ... and Toronto -based 3D visualization ... the Congress of Neurological Surgeons Annual Meeting that ... technologies for brain surgery. The collaboration is the ... powerful combination to improve patient outcomes. NICO,s BrainPath® ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... and INDIANAPOLIS , March 15 ... evaluated response rates in patients with a common genetic ... TRITON-TIMI 38 study were treated with dual antiplatelet therapy ... plus aspirin and managed with percutaneous coronary intervention (PCI) ...
... March 15 At this year,s annual meeting ... 14-16 in Atlanta , Royal Philips Electronics ... simplifying cardiology patient care by highlighting a range of ... tools, intuitive information management systems, new temperature modulation therapies, ...
Cached Medicine Technology:New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 2New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 3New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 4New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 5New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 6New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 7New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 8New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 9New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 10New Analysis Assesses Impact of Common Genetic Variation on Benefit of Antiplatelet Therapy 11Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 2Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 3Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 4Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 5Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 6Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 7Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 8Philips Simplifies Cardiology Care With Technologies That Span the Entire Spectrum of Patient Care 9
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
Keep your laboratory efficient. And meet your volume needs. When you set the pace with the Clinitek 500 Urine Chemistry Analyzer. Its ready when you are. No warm-up. No calibration. No bells. Just pr...
... pressure sensor catheters incorporate a ... injection/guide wire, or high-speed injection/guide ... high-speed injection has two laterally ... an open-end pigtail extension for ...
... catheters provide a simple, efficient and ... in the heart or cardiovascular system. ... ideal for high fidelity pressure measurement. ... 2 to 7 French and in ...
Medicine Products: